Related Experiment Video

Updated: May 29, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K

The Use of Recombinant Activated Factor VII for Controlling Life-threatening Bleeding in Severe Dengue Fever

Arun Agarwal1

  • 1Director and Head, Department of Internal Medicine, Fortis Escorts Hospital, Jaipur, Rajasthan, India, Orcid: https://orcid.org/0000-0001-6449-3914, Corresponding Author.

The Journal of the Association of Physicians of India
|February 2, 2025
PubMed

We report a case of severe dengue fever (DF) in a patient who presented with severe bleeding and discuss the role of recombinant activated factor VII (rFVIIa) in managing life-threatening bleeding in these patients. He presented with spontaneous retroperitoneal, gastrointestinal, and bilateral pleural hemorrhage. In all, 39 units of blood and blood products were transfused within 48 hours of admission, but he continued to experience a drop in hemoglobin. At this stage, the role of rFVIIa was discussed with the family, and he was administered 6 mg of rFVIIa intravenously. Following a single dose of rFVIIa, his ongoing bleeding stopped, and his hemoglobin stabilized. No thromboembolic complications were observed. rFVIIa appears to be a promising intervention in maintaining hemostasis in a subset of severe DF patients who continue to bleed despite all possible efforts. Further studies are warranted.

More Related Videos

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

6.5K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.8K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.6K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.0K